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Abstract
Aims/hypothesis In type 2 diabetes, reduced insulin-
stimulated glucose disposal, primarily glycogen synthesis,
is associated with defective insulin activation of glycogen
synthase (GS) in skeletal muscle. Hyperglycaemia may
compensate for these defects, but to what extent it involves
improved insulin signalling to glycogen synthesis remains
to be clarified.
Methods Whole-body glucose metabolism was studied in
12 patients with type 2 diabetes, and 10 lean and 10 obese
non-diabetic controls by means of indirect calorimetry and
tracers during a euglycaemic-hyperinsulinaemic clamp. The
diabetic patients underwent a second isoglycaemic-
hyperinsulinaemic clamp maintaining fasting hyperglycae-
mia. Muscle biopsies from m. vastus lateralis were obtained
before and after the clamp for examination of GS and
relevant insulin signalling components.
Results During euglycaemia, insulin-stimulated glucose
disposal, glucose oxidation and non-oxidative glucose
metabolism were reduced in the diabetic group compared
with both control groups (p<0.05). This was associated with
impaired insulin-stimulated GS and AKT2 activity, deficient
dephosphorylation at GS sites 2+2a, and reduced Thr308
and Ser473 phosphorylation of AKT. When studied under
hyperglycaemia, all variables of insulin-stimulated glucose
metabolism were normalised compared with the weight-
matched controls. However, insulin activation and dephos-
phorylation (site 2+2a) of GS as well as activation of AKT2
and phosphorylation at Thr308 and Ser473 remained
impaired (p<0.05).
Conclusions/interpretations These data confirm that hyper-
glycaemia compensates for decreased whole-body glucose
disposal in type 2 diabetes. In contrast to previous less well-
controlled studies, we provide evidence that the compensatory
effect of hyperglycaemia in patients with type 2 diabetes does
not involve normalisation of insulin action on GS or upstream
signalling in skeletal muscle.
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PI3K Phosphatidylinositol 3-kinase
RER Respiratory exchange ratio
TBC1D4 TBC1 domain family member 4
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Introduction
Type 2 diabetes is characterised by insulin resistance de-
fined as impaired insulin-stimulated glucose uptake in pe-
ripheral tissues. Skeletal muscle is the major site of glucose
uptake during insulin stimulation, and correspondingly, the
major site of insulin resistance in insulin-resistant conditions
such as type 2 diabetes [1–10]. Reduced insulin-mediated
glucose disposal is accounted for mainly by impaired stim-
ulation of glycogen synthesis [1], but in obesity, polycystic
ovary syndrome (PCOS) and type 2 diabetes also by re-
duced stimulation of glucose oxidation [3–7]. These abnor-
malities are associated with several defects at the molecular
level in insulin-resistant skeletal muscle, including impaired
signalling through proximal and distal components of the
insulin signalling cascade such as the insulin receptor (IR),
insulin receptor substrate-1 (IRS-1), phosphatidylinositol 3-
kinase (PI3K), AKT, and TBC1 domain family, member 4
(TBC1D4), also known as AS160, in many [2, 6, 7, 11–13]
although not all studies [3, 7, 8, 14–16], as well as impaired
insulin activation of glycogen synthase (GS) in most studies
[2–5, 7, 9, 10].
In everyday life, type 2 diabetic patients are characterised
by different degrees of hyperglycaemia, and when studied at
their prevailing fasting hyperglycaemia, the abnormalities in
insulin-stimulated glucose metabolism disappear compared
with weight-matched controls [17–21]. This effect has been
explained by the mass action effect of glucose [21]. Most of
the studies supporting this view were performed before the
majority of components of the insulin signalling cascade
were outlined [22, 23]. Nevertheless, based on the fact that
impaired insulin action on glycogen synthesis was a major
defect [1], a few studies investigated how insulin action on
GS activity was affected by hyperglycaemia in type 2 dia-
betic patients [17–19, 21, 24]. In three studies using phys-
iological levels of insulin [17, 18, 21], it was observed that
hyperglycaemia normalised insulin-stimulated GS fractional
velocity (FV), which reflects the sensitivity of GS to glucose
6-phosphate (G6P) and the degree of GS dephosphorylation
[25]. In two other studies, in which hyperglycaemia was
increased until insulin-stimulated glucose uptake matched
that observed in controls, no effect on GS FV activity was
seen during physiological hyperinsulinaemia [19, 24].
However, these reports all suffer from lack of sufficient
control studies of type 2 diabetic patients during euglycae-
mic conditions [17–19, 21, 24]. If insulin regulation of GS
activity is improved by hyperglycaemia, what are the
molecular mechanisms involved? As GS activity is
measured ex vivo, the changes have to be stable mod-
ifications, i.e. cannot simply be explained by allosteric
mechanisms. One possibility is that an increase in the
allosteric activator, G6P in vivo causes activation of a
phosphatase or deactivation of a kinase affecting GS
phosphorylation [21, 26]. Another possibility is that
hyperglycaemia improves insulin signalling through IR,
IRS-1, PI3K, AKT or glycogen synthase kinase-3
(GSK-3). This remains to be determined.
Since these earlier reports [17–21], it has been shown that
insulin activation of GS is to a major extent mediated by
dephosphorylation of the NH2-terminal sites 2 and 2a, and
the COOH-terminal sites 3a and 3b [22, 25, 27]. We have
shown that type 2 diabetic patients are characterised by
dysregulation at both NH2- and COOH-terminal sites in
skeletal muscle under euglycaemic conditions [3, 7]. Thus,
hyperglycaemia could normalise insulin activation of GS by
decreasing the activity of kinases, which phosphorylate
these sites. Although insulin action on GSK-3 appears nor-
mal in type 2 diabetic patients [3, 7], hyperglycaemia could
still enhance inhibition of GSK-3, the major kinase that
phosphorylates GS at sites 3a, 3b, 3c and 4 [22, 25]. This,
and which sites are affected by hyperglycaemia, if any,
remain to be clarified.
The present study was carried out to examine the molec-
ular mechanisms involved in normalisation of insulin-
mediated glucose metabolism during physiological hyper-
insulinaemia when performed under hyperglycaemic com-
pared with euglycaemic conditions in type 2 diabetic
patients. Skeletal muscle biopsies obtained under both
conditions in patients with type 2 diabetes were pairwise
compared, and also compared with biopsies obtained from
lean healthy and obese non-diabetic individuals, who were
metabolically characterised by euglycaemic clamps and
indirect calorimetry.
Methods
Study participants Twelve obese type 2 diabetic patients care-
fully matched to 10 healthy, lean and 10 obese, non-diabetic
volunteers participated in the study (Table 1). Medication
details and eligibility criteria are given in the electronic
supplementary material (ESM) Methods.
Study design Participants were instructed to refrain from
strenuous physical activity for a period of 48 h before the
experiment. After an overnight fast, the lean and obese
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controls underwent a euglycaemic-hyperinsulinaemic clamp
(4 h of insulin infusion at 40 mU m2 min1) with tracer
glucose and combined with indirect calorimetry (see ESM
Methods) to assess total glucose disposal rates (GDR), res-
piratory exchange ratio (RER), and rates of glucose and
lipid oxidation, and non-oxidative glucose metabolism
(NOGM) as described [28–31]. The diabetic patients were
clamped twice starting randomly with either a euglycaemic
or an isoglycaemic-hyperinsulinaemic clamp separated by
4–6 weeks. Three of twelve diabetic patients could not
participate in the second clamp, leaving paired data for nine
patients. In diabetic patients, plasma glucose was allowed to
decline to 5.5 mmol/l during the euglycaemic clamp before
glucose infusion was initiated, whereas during the isogly-
caemic clamp, glucose infusion was started simultaneously
with insulin infusion in order to clamp plasma glucose at
their prevailing levels of fasting hyperglycaemia. Plasma
glucose and lactate and serum insulin, C-peptide, cholester-
ols, triacylglycerols and NEFA were measured as described
previously [32]. Muscle biopsies were obtained from the
vastus lateralis muscle before and after insulin, and homo-
genates and lysates were prepared as described previously
[33] and in ESM Methods.
Muscle glycogen, glucose and glucose 6-phosphate Muscle
glycogen content was measured in muscle homogenates
(150 μg of protein) as glycosyl units after acid hydro-
lysis determined by a fluorometric method [34]. Muscle
specimens were extracted with perchloric acid, neutral-
ised and analysed for glucose, G6P and uridine diphos-
phate (UDP)-glucose [35] using standard enzymatic
methods [34].
Glycogen synthase activity Muscle GS activity in the pres-
ence of 8, 0.17 or 0.02 mmol/l G6P was measured in
triplicate using a 96-well plate assay (Unifilter 350 Plates,
Whatman, Cambridge, UK) [7, 9]. GS activities are reported
either as total GS activity (determined at 8 mmol/l G6P), the
percentage of G6P-independent GS activity (%I-form)
(100×activity in the presence of 0.02 mmol/l G6P divided
by the activity at 8 mmol/l G6P [saturated]) or as the
percentage of fractional velocity (%FV) (100×activity in
the presence of 0.17 mmol/l G6P divided by the activity at
8 mmol/l G6P).
IRS-1 associated PI3K activity and AKT activities IRS-1
associated PI3K activity was measured on immunoprecipi-
tates of IRS-1 from 300 μg of muscle lysate using an IRS-1
antibody as described (ESM Methods). AKT2 activity was
measured on immunoprecipitates of AKT2 from 300 μg
lysate protein using an anti-AKT2 antibody, and AKT1
activity was measured on 255 μg of the supernatant fraction
from the initial AKT2 immunoprecipitates (ESM Methods).
SDS-PAGE and western blotting Muscle proteins were
separated using 7–10% Tris–HCl gels and transferred (semi-
dry) to PVDF-membranes (Immobilion Transfer Membrane,
Millipore A/S, Denmark) as described previously [33]. Iso-
form (AKT1 and AKT2)-specific phosphorylation (Thr308
and Ser473) was determined by prior isoform-specific immu-
noprecipitation from 200 μg of protein following western
blotting. Tyrosine phosphorylation of the IR was also deter-
mined by prior immunoprecipitation of the IR from 300 μg of
lysate protein. A list of the antibodies used is given in ESM
Methods. By loading a control sample in different amounts, it
Table 1 Subject characteristics
at study entry
Data are mean±SEM
*p<0.05, **p<0.01, and
***p<0.001 vs obese controls;
†p<0.05, ††p<0.01, and
†††p<0.001 vs lean controls
Characteristic Lean controls Obese controls Type 2 diabetes
n 10 10 12
Sex (male/female) 4/6 6/4 6/6
Age (years) 54.0±1.5 55.4±1.2 53.5±1.7
BMI (kg/m2) 23.2±0.6 31.1±0.9††† 29.1±1.2†††
Fat free mass (kg) 51.1±4.1 63.0±4.2 55.3±3.2
Fat mass (kg) 17.8±1.1 30.3±1.9†† 27.8±2.5††
Plasma glucose (mmol/l) 5.6±0.1 5.8±0.1 8.5±0.6***,†††
Serum insulin (pmol/l) 32±5 40±6 68±12†
Serum C-peptide (pmol/l) 520±33 633±45 1053±136**,††
HbA1c (%) 5.4±0.1 5.3±0.1 6.7±0.3***
,††
Plasma cholesterol (mmol/l) 5.6±0.3 5.1±0.3 4.9±0.2
Plasma LDL-cholesterol (mmol/l) 3.6±0.2 3.2±0.3 3.2±0.2
Plasma HDL-cholesterol (mmol/l) 1.7±0.1 1.6±0.1 1.1±0.1**,†††
Plasma triacylglycerols (mmol/l) 0.85±0.08 1.0±0.13 1.54±0.14*,††
Plasma NEFA (mmol/l) 0.45±0.05 0.41±0.03 0.53±0.06
Diabetes duration (years) – – 6.3±1.5
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was ensured that the quantification was within the linear
response range for each particular protein probed for. An
example of the whole gel set-up is given in ESM (Fig. 1).
Statistics Statistical analyses were performed using Sigma-
Stat version 3.5 (Systat Software, San Jose, CA, USA). Data
are presented as means±SEM. Differences between the
groups were analysed by two-way ANOVA for one-way
repeated measures, and significant main effects were further
analysed by the Tukey post hoc test. p values below 0.05
were considered significant.
Results
Clinical and metabolic characteristics At study entry,
fasting levels of plasma glucose, glycated haemoglobin
(HbA1c), plasma triacylglycerols and serum C-peptide were
elevated and HDL-cholesterol reduced in the diabetic group
compared with both control groups, whereas fasting serum
insulin was higher in the diabetic group compared with the
lean controls (Table 1).
During the insulin-stimulated steady-state period of the
euglycaemic clamp, physiological hyperinsulinaemia, at a
serum insulin concentration of ~400 pmol/l, was observed in
all groups (Table 2). GDR, glucose oxidation and NOGM
were similar among groups in the basal steady-state period.
GDR and glucose oxidation were increased by insulin in all
three groups (p<0.05), whereas NOGM was increased only
in the two control groups (p<0.05). In the diabetic group,
insulin-stimulated GDR, glucose oxidation and NOGM
were reduced compared with both control groups (Table 2).
Insulin-stimulated GDR and NOGM in obese controls were
also lower than in lean controls. The ability of insulin to
suppress lipid oxidation and to increase RER was reduced in
diabetic patients compared with both lean and obese
controls.
In the diabetic group clamped at prevailing levels of
fasting hyperglycaemia (isoglycaemic clamp), serum insulin
rose to 525 pmol/l during the insulin-stimulated steady-state
period. Pairwise comparison of the diabetic patients who
underwent both isoglycaemic and euglycaemic clamp stud-
ies showed that hyperglycaemia significantly increased
insulin-mediated GDR, glucose oxidation and NOGM
(Table 2). The average increase in insulin action on NOGM
observed in these diabetic patients accounted for 76% of the
increase in GDR. Compared with the matched obese con-
trols, insulin-stimulated RER, GDR, glucose oxidation and
NOGM were normalised in the diabetic group clamped at
hyperglycaemia. However, insulin-stimulated GDR and
NOGM were still slightly reduced in obese diabetic patients
compared with lean controls. To account for the additional
increase in serum insulin during the isoglycaemic clamp
compared with the euglycaemic clamp, we calculated
Table 2 Metabolic characteristics
during clamp
Data are mean±SEM
n09 for diabetic patients
when isoglycaemic (T2D-Iso)
and euglycaemic (T2D-Eu)
clamp data are compared
All variables changed significant-
ly in response to insulin
(p<0.05), except for lactate in
all groups, and NOGM in
T2D-Eu
*p<0.05, **p<0.01, and
***p<0.001 vs obese controls;
†p<0.05, ††p<0.01, and
†††p<0.001 vs lean controls
(¶p<0.10); ‡ p<0.05,
‡‡p<0.01, and ‡‡‡p<0.001 vs
euglycaemic clamp
Characteristic Lean
(n010)
Obese
(n010)
T2D-Eu
(n010)
T2D-Iso (n011)
Plasma glucose, basal (mmol/l) 5.6±0.1 5.8±0.1 8.9±0.7***,††† 9.2±0.7***,†††
Plasma glucose, clamp (mmol/l) 5.5±0.1 5.4±0.1 5.4±0.1 9.3±0.7***,†††,‡‡‡
Serum insulin, basal (pmol/l) 19±2 33±7 69±14† 74±20
Serum insulin, clamp (pmol/l) 417±18 397±15 428±14 525±49*,††,‡‡
GDR, basal (mg min−1 m−2) 77±3 74±6 73±3 83±3
GDR, clamp (mg min−1 m−2) 378±28 309±24† 160±26***,††† 298±37†,‡‡‡
GDR per insulin, clamp
(mg min−1 m−2nmol/l−1)
928±91 804±81 385±70**,††† 653±113‡
Glucose oxidation, basal (mg min−1 m−2) 52±6 48±4 48±9 75±8
Glucose oxidation, clamp (mg min−1 m−2) 142±11 131±12 91±7**,††† 119±11‡
NOGM, basal (mg min−1 m−2) 24±4 26±6 25±7 8 ±7
NOGM, clamp (mg min−1 m−2) 236±21 178±25† 69±21***,††† 160±30¶,‡‡‡
Lipid oxidation, basal (mg min−1 m−2) 26±2 31±2 36±4 26±3‡
Lipid oxidation, clamp (mg min−1 m−2) −4±4 1±4 16±4*,††† 11±4
RER, basal 0.82±0.01 0.81±0.01 0.80±0.01 0.84±0.01
RER, clamp 0.99±0.02 0.96±0.02 0.90±0.02*,††† 0.96±0.02‡
Lactate, basal (mmol/l) 0.70±0.06 0.74±0.06 1.14±0.11**,††† 1.23±0.11***,†††
Lactate, clamp (mmol/l) 1.30±0.08 1.19±0.09 1.01±0.07 1.24±0.11
NEFA, basal (mmol/l) 0.45±0.05 0.41±0.03 0.54±0.06 0.59±0.1¶
NEFA, clamp (mmol/l) 0.01±0.01 0.02±0.01 0.08±0.02 0.05±0.01††
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GDR per insulin unit in the insulin-stimulated periods.
This showed that isoglycaemic clamp in type 2 diabetic
patients still significantly increased insulin action on
GDR, and actually abolished any significant difference
when compared with both lean and obese controls
(Table 2). The analyses gave similar results when cal-
culated as mg min−1 (kg fat free mass)−1 rather than
mg min−1 m−2 (ESM Table 1).
Plasma lactate levels in the basal state were increased in
diabetic patients compared with controls. No differences
between the groups were seen in the insulin-stimulated state,
and no effect of the isoglycaemic clamp was observed in
type 2 diabetic patients (Table 2).
Glycogen synthase To test whether the improved insulin-
stimulated GDR and primarily NOGM was mediated by
improved insulin activation of GS, we measured protein
content, activity and phosphorylation of GS (Fig. 1). No
differences in GS protein content or total GS activity were
observed between the four groups. Moreover, in all four
groups, insulin significantly increased GS activity measured
as both %I-form and %FV. In the diabetic groups clamped at
either euglycaemia or hyperglycaemia, insulin-stimulated
GS activities were reduced compared with the control
groups. Pairwise comparison of the diabetic patients who
underwent both isoglycaemic and euglycaemic clamp stud-
ies showed no effect of the isoglycaemic clamp on the
ability of insulin to activate GS. Thus, the normalised insu-
lin action on GDR and NOGM during an isoglycaemic
clamp in the diabetic group is not explained by improve-
ments in insulin activation of GS as measured ex vivo.
In the control groups, physiological hyperinsulinae-
mia significantly reduced phosphorylation of GS at
sites 2+2a and 3a+3b, whereas in diabetic patients,
no effect of insulin on GS phosphorylation at sites
2+2a was seen during either the euglycaemic or the
isoglycaemic clamp (Fig. 2). Although insulin signifi-
cantly reduced GS phosphorylation at sites 3a+3b only
during the isoglycaemic clamp in the diabetic patients,
no enhancing effect of the isoglycaemic clamp on either
sites 3a+3b, sites 2+2a, or site 1b compared with the
euglycaemic clamp was demonstrated. Thus, these data
correspond to the GS activities. Insulin-mediated phos-
phorylation of GSK-3α and -β, were not different
between the groups, and in accordance with GS activity
and phosphorylation, insulin-mediated phosphorylation
of GSK-3α and -β were not affected by the isoglycae-
mic clamp versus the euglycaemic clamp in the diabetic
group (Fig. 2).
Proximal insulin signalling To investigate whether the im-
proved insulin action on GDR mediated by the isoglycaemic
clamp was paralleled by improved insulin signalling to GS,
we measured insulin action on IR tyrosine phosphorylation,
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IRS-1 associated PI3K activity and AKT activity/phosphor-
ylation (Fig. 3, ESM Fig. 2). Physiological hyperinsulinae-
mia increased tyrosine phosphorylation of the IR in all
groups (main effect p<0.001). Although a main effect of
diabetes (p00.042) was seen during the euglycaemic clamp,
there was no interaction between groups and clamp level
(basal vs insulin). Moreover, when corrected for IR protein
content, no difference was evident between groups (ESM
Fig. 2). Physiological hyperinsulinaemia increased IRS-1-
associated-PI3K activity in all four groups. Although basal
IRS-1-associated-PI3K activity appeared elevated leading to
an apparently smaller increment in response to insulin in the
diabetic group, there were no significant differences be-
tween the diabetic and control groups, and no effect of the
isoglycaemic clamp in the diabetic group (Fig. 3). ANOVA
showed a tendency for a difference in insulin-induced fold-
changes in IRS-1-associated-PI3K activity between the lean
(3.17±0.49), obese (2.76±0.48) and diabetic groups (1.74±
0.27) during the euglycaemic clamp (main effect p0
0.06), but not during the isoglycaemic clamps (diabetic
group; 1.99±0.40, main effect p00.18), and there was
no effect of the isoglycaemic clamp in the diabetic
group (p00.46). In contrast, insulin-stimulated phos-
phorylation of AKT at Thr308 and Ser473, and activa-
tion and Thr308 phosphorylation of immunoprecipitated
AKT2 were significantly impaired in the diabetic groups
compared with the control groups (Fig. 3). This defect
was unrelated to AKT2 protein content (similar between
groups, ESM Figs 3 and 4). The isoglycaemic clamp
did not abolish these defects in type 2 diabetic patients.
It is noteworthy that in skeletal muscle, insulin activa-
tion of AKT was isoform-specific as no regulation of
AKT1 activity was evident (ESM Fig. 5) and no AKT3
protein was detected (data not shown). Thus, no
changes in insulin action on these proximal components
of the insulin signalling cascade could explain the
0
20
40
60
80
100
120
Ph
os
ph
o 
G
S 
sit
e 
2+
2a
(A
U)
a
**
**
0
50
100
150
200
250
Ph
os
ph
o 
G
S 
sit
e 
3a
+3
b
(A
U)
b
Lean Obese T2D-IsoT2D-Eu
Lean Obese T2D-IsoT2D-Eu
Lean Obese T2D-IsoT2D-Eu
Lean Obese T2D-IsoT2D-Eu
Lean Obese T2D-IsoT2D-Eu
Lean Obese T2D-IsoT2D-Eu
*** **
*
0
40
80
120
160
200
Ph
os
ph
o 
G
S 
sit
e 
1b
(A
U)
c
0
300
600
900
1,200
1,500
1,800
Ph
os
ph
o 
G
SK
3α
 S
er
21
(A
U)
e
0
400
800
1,200
1,600
Ph
os
ph
o 
G
SK
3β
 Se
r9
(A
U)
 
d
***
***
***
***
f
pGS site 2+2a
pGS site 3a+3b
pGS site 1b
pGSK-3β Ser9
pGSK-3α Ser21
Insulin        − + − + − + − +
Fig. 2 Phosphorylation
of GS at sites 2+2a (a), site
3a+3b (b) and site 1b (c), and
phosphorylation of glycogen
synthase kinase 3β (GSK3β) at
Ser9 (d) and GSK3α at Ser21
(e). Findings are shown in
representative immunoblots (f),
quantified in bar graphs as
arbitrary units (AU).
Measurements were performed
in skeletal muscle biopsies
obtained from lean, obese
and type 2 diabetic (T2D-Eu)
individuals during the
basal (white bars) and
insulin-stimulated (black
bars) steady-state periods
of a 4-h euglycaemic-
hyperinsulinaemic clamp.
T2D individuals (T2D-Iso)
also underwent a isoglycaemic-
hyperinsulinaemic clamp.
Data are means±SEM.
*p<0.05, **p<0.01 and
***p<0.001 vs basal
1440 Diabetologia (2012) 55:1435–1445
improvements in GDR caused by the isoglycaemic
clamp in patients with type 2 diabetes.
Intracellular glucose, G6P, UDP-glucose and glycogen We
next examined whether the improved insulin action on GDR
during the isoglycaemic clamp was accompanied by
changes in intracellular levels of glucose, G6P, UDP-
glucose or glycogen in muscle biopsies. We were not able
to demonstrate any differences between the diabetic and
control groups, or between the isoglycaemic and euglycae-
mic clamp in type 2 diabetic patients either in the basal or
the insulin-stimulated steady-state periods (Table 3). As
reported in rodent muscle [35], insulin significantly reduced
intracellular levels of UDP-glucose (p<0.001, main effect)
in the present study with no significant difference between
the groups. In both control groups, insulin significantly
increased glycogen levels (p<0.05), whereas no such effect
was seen in the diabetic groups clamped at either euglycaemia
or hyperglycaemia.
Discussion
Several studies have shown that insulin-stimulation of glu-
cose disposal is normalised in type 2 diabetic patients if
investigated at their prevailing fasting hyperglycaemia
[17–21]. In agreement, we demonstrate by direct compari-
son, that hyperglycaemia normalises insulin-mediated GDR
in type 2 diabetic patients compared with weight-matched
non-diabetic individuals, and that normalisation of NOGM
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Fig. 3 IRS-1 associated PI3K
activity (a), AKT2 activity (b),
Thr308 phosphorylation of
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Findings are shown in
representative immunoblots (g
and h), quantified in bar graphs
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min−1 mg−1). Measurements
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accounts for ~75% of this improvement. The major findings
of the present study were, however, that contrary to our
working hypothesis, and previous less well-controlled stud-
ies [17, 18, 21], hyperglycaemia did not abolish defective
insulin activation of GS, or related deficient dephosphory-
lation at sites 2+2a in the muscle of patients with type 2
diabetes [2, 3, 7]. Moreover, impaired insulin signalling to
GS via AKT phosphorylation at Thr308 and Ser473 was not
repaired by hyperglycaemia. Finally, we did not detect any
changes in intramyocellular levels of glucose, G6P, UDP-
glucose or glycogen in response to hyperglycaemia that
could explain improved glucose metabolism. We, therefore,
conclude that normalisation of whole-body insulin-mediated
glucose metabolism does not involve improved insulin sig-
nalling to GS via AKT or dephosphorylation of GS. Thus,
further studies are warranted to elucidate the molecular
mechanism underlying this beneficial effect of hyperglycaemia
during clamp conditions.
Our results are in line with an earlier study of the effect of
hyperglycaemia in healthy individuals [36]. Thus, during a
4 h hyperglycaemic clamp using an insulin infusion rate of
40 mU min−1 m−2, no effect of hyperglycaemia (10 mmol/l)
was seen on insulin activation of GS, despite large increases
in GDR and NOGM [36]. Moreover, in agreement with our
data, no effect was seen on glycogen levels, probably be-
cause the expected increase due to improved glycogen syn-
thesis is below 10%, and therefore difficult to detect [36].
Concerning GS, our findings are in contrast to most previ-
ous studies of type 2 diabetic patients during hyperglycae-
mia [17–19, 21]. In these studies, the diabetic patients were,
however, examined only during hyperglycaemia, and not
during euglycaemia [18, 19, 21], or only a few patients
(n04) were studied under euglycaemia [17]. In those studies
that reported an apparently normalised GS activity during
hyperglycaemia [17, 18, 21], the isoglycaemic clamp
procedure was very similar to the one used in the present
study. Thus, the lack of effect on GS activity in our study
cannot be explained by differences in the insulin concentration
used or duration of infusion. Although we and others have
demonstrated impaired insulin activation of GS in type 2
diabetes [2, 3, 7], not all studies have been able to detect a
significant difference between obese type 2 diabetic patients
and matched non-diabetic individuals [7, 10]. Without suffi-
cient control clamps performed at euglycaemia in type 2
diabetic patients, it remains a possibility that the apparently
normal insulin action on GS activity observed during hyper-
glycaemia in previous studies does not represent a true im-
provement [17, 18, 21]. In two studies, which also reported a
lack of effect on GS activity, the study design was quite
different using 5-h insulin infusion and aiming for hypergly-
caemia (20 mmol/l) that normalised glucose uptake [19, 24].
This caused a decrease in insulin stimulation of glucose oxi-
dation whereas NOGMwas markedly increased. The increase
in NOGM was explained by increased non-oxidative glycol-
ysis, which leads to exaggerated muscle lactate production,
and was suggested to increase flow through the Cori cycle
[19]. This was supported by the finding of a pronounced
increase in plasma lactate in the insulin-stimulated state in
response to hyperglycaemia [19]. In our study, the increase in
NOGM cannot be explained by this mechanism. Thus, glu-
cose oxidation was also increased, and plasma lactate levels in
the insulin-stimulated state were not increased in type 2 dia-
betic patients clamped at hyperglycaemia compared with
euglycaemia, or even compared with controls.
Using an insulin infusion rate of 40 mU min−1 m−2, we
observed a 20% higher increase in plasma insulin levels
during the isoglycaemic clamp compared with the euglycae-
mic clamp. However, even after adjustment for this addi-
tional increase in insulin, insulin-mediated GDR were
normalised in type 2 diabetic patients compared with
Table 3 Intramyocellular concentrations of glycogen, G6P, UDP-glucose and glucose
Lean (n010) Obese (n010) T2D-Eu (n010) T2D-Iso (n011)
Glycogen, basal (mmol/kg dw) 393±37 382±52 394±17 436±39
Glycogen, clamp (mmol/kg dw) 479±30 471±36 415±31 460±32
G6P, basal (mmol/kg dw) 0.56±0.20 0.40±0.06 0.32±0.08 0.63±0.27
G6P, clamp (mmol/kg dw) 0.34±0.09 0.39±0.09 0.36±0.07 0.32±0.07
UDPG, basal (mmol/kg dw) 0.098±0.015 0.100±0.009 0.095±0.007 0.118±0.006
UDPG, clamp (mmol/kg dw) 0.073±0.006 0.073±0.009 0.083±0.009 0.066±0.008
Glucose, basal (mmol/kg dw) 6.35±1.17 6.18±0.73 8.09±0.82 9.20±1.30
Glucose, clamp (mmol/kg dw) 5.99±0.87 4.12±0.58 5.91±1.25 7.37±1.20
Data are mean±SEM
n09 for diabetic patients when isoglycaemic (T2D-Iso) and euglycaemic (T2D-Eu) clamp data are compared
Insulin decreased concentrations of UDP-glucose in all groups (p<0.001, main effect), and increased glycogen levels in both control groups (p<
0.05), but not in the diabetic groups
dw, dry weight
1442 Diabetologia (2012) 55:1435–1445
controls. Higher levels of insulin were also observed in a
previous study reporting a positive effect of hyperglycaemia
on glucose metabolism and GS in patients with type 2
diabetes [21]. Despite this extra increase in insulin, we could
not demonstrate any beneficial effect of the isoglycaemic
clamp on insulin action on GS FV, dephosphorylation of GS
or signalling from the IR through PI3K and AKT to GSK-3.
This indicates that skeletal muscle was unaffected by this
minor increase in insulin. This is supported by the study of
Kelley et al. [17], in which the ability of hyperglycaemia to
normalise insulin action on glucose metabolism and GS was
observed at comparable levels of hyperinsulinaemia in
controls and diabetic patients.
Of interest, we could not reproduce the finding of in-
creased phosphorylation of muscle GS at site 1b in type 2
diabetic patients [7]. Similar to the inconsistent finding of
impaired insulin action on AKT phosphorylation (6,7,11–
13), this probably reflects the large heterogeneity in both
type 2 diabetic and obese non-diabetic individuals combined
with the relatively small sample sizes often used in such
studies. However, the impaired insulin activation of GS and
the lack of dephosphorylation of GS at sites 2+2a appear to
be consistent findings in type 2 diabetic patients [3, 7], as
well as in other insulin-resistant conditions such as PCOS
[9] and HIV lipodystrophy [37]. Consistently, we have
demonstrated that insulin-mediated dephosphorylation of
GS at sites 2+2a correlates significantly with insulin-
stimulated NOGM in a large cohort of twins [38]. Currently,
it appears that insulin resistance in muscle of type 2 diabetes
is associated with defect insulin activation of GS [2–4, 7,
10], deficient dephosphorylation of GS at sites 2+2a [3, 7]
and impaired activation of AKT2 and phosphorylation of
AKT at Thr308 and Ser473 [7, 11]. Whether dephosphory-
lation of GS sites 3a+3b is also impaired in type 2 diabetes
remains a possibility. In this and two previous studies [3, 7],
we have, however, been unable to demonstrate a significant
reduction in the insulin-mediated dephosphorylation of sites
3a+3b in type 2 diabetic patients, although the effect has
seemed lower in all three studies. Moreover, these sites are
to a major extent regulated by GSK-3 during insulin stimu-
lation [22, 25], and in none of our studies was any evidence
found that the ability of insulin to inhibit GSK-3 is compro-
mised in skeletal muscle of type 2 diabetic patients.
Importantly, none of the signalling defects observed dur-
ing euglycaemia in muscle of type 2 diabetic patients were
restored by hyperglycaemia during a hyperinsulinaemic
clamp, and there was no improvement in signalling through
either IR, PI3K or AKT. This lack of effect of hyperglycae-
mia on insulin signalling has to our knowledge not been
demonstrated in human skeletal muscle before. Although
these findings lend support to the hypothesis [20] that the
effect of hyperglycaemia is mediated by a mass action, there
is accumulating experimental evidence that glucose
transport via GLUT4 is regulated by several distinct mech-
anisms including exocytosis, endocytosis and intrinsic
activity of GLUT4 [23]. Hyperglycaemia during a hyper-
insulinaemic clamp may regulate one or more of the
enzymes involved in these processes in skeletal muscle of
both healthy and type 2 diabetic patients. Moreover, we
cannot exclude the possibility that hyperglycaemia repairs
an abnormality in insulin signalling to glucose transport
further downstream of the AKT→TBC1D4/TBC1D1→
Rab axis, via selective actin remodelling through the
Rac→actin→α-actinin-4 axis, changes in binding of
GLUT4 interacting proteins such as GAPDH and hexoki-
nase II, or a defect in enzymes mediating fusion of GLUT4
vesicles with the plasma membrane such as synaptosomal-
associated protein 23 (SNAP23), mammalian homologue of
Unc-18c (MUNC18C), syntaxin4 and vesicle associated
membrane protein 2 (VAMP2) [23, 39]. Thus, studies of
the several processes that regulate GLUT4 vesicle move-
ment, and content and activity in the plasma membrane in
response to hyperglycaemia may help to reveal the mecha-
nisms involved in improved insulin-mediated glucose me-
tabolism during a hyperglycaemic hyperinsulinaemic clamp.
In contrast to previous studies measuring G6P in human
muscle using magnetic resonance spectroscopy [40], we
could not demonstrate an increase in muscle G6P in re-
sponse to physiological hyperinsulinaemia, or in response
to hyperglycaemia during insulin stimulation. Thus, in our
hands, changes in muscle G6P concentrations do not seem
to explain increased insulin-mediated glycogen synthesis
during hyperglycaemia. Although the lack of response to
insulin has been reported before using the same biochemical
assay [21], the cause of these discrepancies remains to be
defined. We therefore measured muscle levels of UDP-
glucose. As reported in mouse muscle [35], we observed
that insulin caused a significant reduction in muscle UDP-
glucose. However, there was no difference between diabetic
and non-diabetic groups, and, most importantly, no effect of
hyperglycaemia on UDP-glucose that could explain im-
proved insulin-mediated glycogen synthesis. Our data do not
exclude an increased flux of G6P or UDP-glucose in response
to hyperglycaemia, and this may push the control of GS
activity toward a more G6P-dependent activation in vivo.
In summary, we confirm that hyperglycaemia normalises
insulin-mediated GDR, primarily due to improved NOGM
in type 2 diabetic patients. The novel finding is that this
effect is achieved without improved insulin signalling
through IR, PI3K, AKT and GS, or changes in the intra-
myocellular levels of glucose metabolites. These results
support the view that hyperglycaemia works by the mass
action effect of glucose. However, we cannot exclude the
possibility that hyperglycaemia could augment insulin-
mediated glucose uptake by molecular mechanisms yet to
be defined, and that this augmentation could bypass the
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defects in insulin action on key enzymes regulating glucose
transport and glycogen synthesis. If such mechanisms could
be identified, they may represent novel targets for treatment.
That is, if a similar beneficial effect could be achieved
without a sustained increase in glucose levels.
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